Clin Genet. 2010 Jul;78(1):1-7. doi: 10.1111/j.1399-0004.2010.01402.x.

Testing for CHEK2 in the cancer genetics clinic: ready for prime time?

Source

Womens College Research Institute, 790 Bay, Toronto, Ontario, Canada. Steven.narod@wchospital.ca

Abstract

The 1100delC mutation of the CHEK2 gene was found to be a cause of breast cancer in 2002. The lifetime risk of breast cancer among women with a mutation and with a family history of breast cancer is approximately 25%. These women are good candidates for screening with MRI and for chemoprevention with tamoxifen. It is reasonable to test for this single mutation when women undergo testing for BRCA1 and BRCA2.

PMID:: 20597917; [PubMed - indexed for MEDLINE]

Publication Types, MeSH Terms, Substances

Publication Types

Review

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Molecular Biology Databases

TAMOXIFEN - HSDB

Supplemental Content

Save items

Related citations in PubMed

Review CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls. [J Clin Oncol. 2008]
Review CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls.
Weischer M, Bojesen SE, Ellervik C, Tybjaerg-Hansen A, Nordestgaard BG. J Clin Oncol. 2008 Feb 1; 26(4):542-8. Epub 2008 Jan 2.
Risk of breast cancer in women with a CHEK2 mutation with and without a family history of breast cancer. [J Clin Oncol. 2011]
Risk of breast cancer in women with a CHEK2 mutation with and without a family history of breast cancer.
Cybulski C, Wokołorczyk D, Jakubowska A, Huzarski T, Byrski T, Gronwald J, Masojć B, Deebniak T, Górski B, Blecharz P, et al. J Clin Oncol. 2011 Oct 1; 29(28):3747-52. Epub 2011 Aug 29.
Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. [JAMA. 2006]
Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.
Walsh T, Casadei S, Coats KH, Swisher E, Stray SM, Higgins J, Roach KC, Mandell J, Lee MK, Ciernikova S, et al. JAMA. 2006 Mar 22; 295(12):1379-88.
The CHEK2 1100delC mutation is not present in Korean patients with breast cancer cases tested for BRCA1 and BRCA2 mutation. [Breast Cancer Res Treat. 2008]
The CHEK2 1100delC mutation is not present in Korean patients with breast cancer cases tested for BRCA1 and BRCA2 mutation.
Choi DH, Cho DY, Lee MH, Park HS, Ahn SH, Son BH, Haffty BG. Breast Cancer Res Treat. 2008 Dec; 112(3):569-73. Epub 2008 Jan 3.
Review [Genetic test and prophylactic treatment in breast cancer families]. [Gan To Kagaku Ryoho. 2002]
Review [Genetic test and prophylactic treatment in breast cancer families].
Miyoshi Y, Noguchi S. Gan To Kagaku Ryoho. 2002 Apr; 29(4):512-22.

See reviews... See all...

Cited by 7 PubMed Central articles

The tip of the iceberg: a countercurrents series. [Curr Oncol. 2012]
The tip of the iceberg: a countercurrents series.
Narod SA. Curr Oncol. 2012 Jun; 19(3):129-30.
CHEK2 contribution to hereditary breast cancer in non-BRCA families. [Breast Cancer Res. 2011]
CHEK2 contribution to hereditary breast cancer in non-BRCA families.
Desrichard A, Bidet Y, Uhrhammer N, Bignon YJ. Breast Cancer Res. 2011; 13(6):R119. Epub 2011 Nov 24.
Genetic testing for familial/hereditary breast cancer-comparison of guidelines and recommendations from the UK, France, the Netherlands and Germany. [J Community Genet. 2011]
Genetic testing for familial/hereditary breast cancer-comparison of guidelines and recommendations from the UK, France, the Netherlands and Germany.
Gadzicki D, Evans DG, Harris H, Julian-Reynier C, Nippert I, Schmidtke J, Tibben A, van Asperen CJ, Schlegelberger B. J Community Genet. 2011 Jun; 2(2):53-69. Epub 2011 Mar 2.

See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

Testing for CHEK2 in the cancer genetics clinic: ready for prime time?
Testing for CHEK2 in the cancer genetics clinic: ready for prime time?
Clin Genet. 2010 Jul ;78(1):1-7. doi: 10.1111/j.1399-0004.2010.01402.x.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to: